Seres Therapeutics, Inc. (MCRB) — 8-K Filings

8-K Filings (29)

• 8-K Filing — May 5, 2026
• Seres Therapeutics Files 8-K for Other Events — Oct 3, 2025 Risk: low
  Seres Therapeutics, Inc. filed an 8-K on October 3, 2025, reporting an event on September 23, 2025. The filing pertains to 'Other Events' and does not specify a
• Seres Therapeutics Files 8-K on Financials — Aug 6, 2025 Risk: low
  Seres Therapeutics, Inc. filed an 8-K on August 6, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD
• Seres Therapeutics Announces Board and Executive Changes — Jul 22, 2025 Risk: medium
  Seres Therapeutics, Inc. announced on July 17, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company report
• Seres Therapeutics Files 8-K on Financials — May 7, 2025 Risk: low
  On May 7, 2025, Seres Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, along w
• Seres Therapeutics Updates Fiscal Year End — Apr 22, 2025 Risk: low
  On April 21, 2025, Seres Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's fiscal year end to December 31st. This is a rout
• Nestlé to Acquire Seres Therapeutics for $1.9B — Apr 14, 2025 Risk: medium
  Seres Therapeutics, Inc. announced on April 10, 2025, that it has entered into a definitive agreement to be acquired by Nestlé Health Science for approximately
• 8-K Filing — Mar 13, 2025
• Seres Therapeutics Announces Board and Executive Changes — Feb 27, 2025 Risk: medium
  Seres Therapeutics, Inc. announced on February 22, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depar
• Seres Therapeutics Announces Board and Officer Changes — Feb 6, 2025 Risk: low
  Seres Therapeutics, Inc. announced on February 4, 2025, changes in its board of directors and executive compensation. Specifically, the company elected new dire
• 8-K Filing — Jan 13, 2025
• Seres Therapeutics Files 8-K on Operations and Financials — Jan 10, 2025 Risk: low
  On January 9, 2025, Seres Therapeutics, Inc. filed an 8-K report detailing results of operations and financial condition, along with other events and financial
• Seres Therapeutics 8-K: Delisting Notice & Financials — Nov 13, 2024 Risk: high
  Seres Therapeutics, Inc. filed an 8-K on November 13, 2024, reporting on its results of operations and financial condition. The filing also disclosed a notice o
• Seres Therapeutics Terminates Nestle Health Science Agreement — Oct 1, 2024 Risk: medium
  On September 30, 2024, Seres Therapeutics, Inc. announced the termination of its material definitive agreement with Nestle Health Science. This termination is r
• Seres Therapeutics Files 8-K Report — Sep 26, 2024 Risk: low
  On September 26, 2024, Seres Therapeutics, Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements.
• Nestlé to Acquire Seres Therapeutics for $1.9 Billion — Sep 12, 2024 Risk: medium
  Seres Therapeutics, Inc. announced on September 12, 2024, that it has entered into a definitive agreement to be acquired by Nestlé S.A. for $5.30 per share in c
• Seres Therapeutics Files 8-K with Financial Updates — Aug 15, 2024 Risk: low
  On August 15, 2024, Seres Therapeutics, Inc. filed an 8-K report detailing financial statements and exhibits. The filing includes information related to lease a
• Seres Therapeutics Files 8-K on Financials — Aug 13, 2024 Risk: low
  On August 13, 2024, Seres Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, alo
• Seres Therapeutics Files 8-K Report — Aug 6, 2024 Risk: low
  On August 6, 2024, Seres Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No s
• Seres Therapeutics Files 8-K on Financials — May 8, 2024 Risk: low
  Seres Therapeutics, Inc. filed an 8-K on May 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements a
• Seres Therapeutics Reports Financial Obligation Event — May 7, 2024 Risk: medium
  On May 1, 2024, Seres Therapeutics, Inc. reported a triggering event related to its financial obligations. This filing indicates an acceleration or increase in
• Seres Therapeutics Faces Delisting Concerns — Apr 23, 2024 Risk: high
  Seres Therapeutics, Inc. filed an 8-K on April 23, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of April
• Seres Therapeutics Files 8-K on Fiscal Year Change — Apr 8, 2024 Risk: low
  Seres Therapeutics, Inc. filed an 8-K on April 8, 2024, reporting on events that occurred on April 4, 2024. The filing indicates a change in the company's fisca
• Seres Therapeutics Files 8-K on Financials — Mar 5, 2024 Risk: low
  On March 5, 2024, Seres Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's financial condition and results of operations. It al
• Seres Therapeutics Reports Officer Changes and Disclosure — Feb 26, 2024 Risk: medium
  Seres Therapeutics, Inc. filed an 8-K on February 26, 2024, reporting an event that occurred on February 24, 2024. The filing pertains to Item 5.02, "Departure
• Seres Therapeutics Updates Principal Executive Offices — Jan 30, 2024
  Seres Therapeutics, Inc. (MCRB) filed an 8-K on January 30, 2024, to update its principal executive offices to 101 Cambridgepark Drive, Cambridge, MA 02140. Thi
• Seres Therapeutics Files 8-K on Financial Condition Update — Jan 10, 2024
  Seres Therapeutics, Inc. (MCRB) filed an 8-K on January 10, 2024, reporting an event that occurred on January 9, 2024, related to its 'Results of Operations and
• Seres Therapeutics Updates Principal Executive Office Address — Jan 9, 2024
  Seres Therapeutics, Inc. filed an 8-K on January 9, 2024, primarily to update its principal executive offices from 200 Sidney Street, 4th Floor, Cambridge, MA 0
• Seres Therapeutics Enacts 1-for-10 Reverse Stock Split — Jan 2, 2024
  Seres Therapeutics, Inc. (MCRB) filed an 8-K on January 2, 2024, to report an amendment to its Certificate of Incorporation. This amendment, approved by stockho

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX